CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its "reasonable best efforts" public offering with participation from a member of the Company's board and a single institutional investor for the purchase and sale of 2,551,020 shares of its common s ...